Clinical Study Highlights the Potential of Probiotic IDCC 3201 for IBS-C Symptom Relief
Irritable bowel syndrome with constipation (IBS-C) is a common gastrointestinal disorder characterized by abdominal discomfort, bloating, and irregular bowel movements. Growing research suggests that gut microbiota modulation through probiotics may offer new approaches to supporting digestive health.
A clinical study published in Scientific Reports (2024) investigated the effects of Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201), a probiotic strain developed by ILDONG Bioscience.
The randomized, double-blind, placebo-controlled study involved 30 participants with IBS-C who received either RH 3201 (10 billion CFU daily) or a placebo for eight weeks.
The results demonstrated significant improvements in bowel movement frequency, constipation-related discomfort, and overall IBS symptom severity in the RH 3201 group. Participants also experienced improvements in abdominal bloating and bowel habit satisfaction, alongside better IBS-related quality of life.
Beyond clinical symptoms, researchers observed changes in gut microbiota composition, including increased abundance of Akkermansia muciniphila and Bacteroides cellulosilyticus. Metabolomic analysis also identified changes in specific gut metabolites, suggesting a potential relationship between microbiome modulation and digestive health.
These findings provide valuable clinical evidence supporting the potential of strain-specific probiotics in gut health applications.
At ILDONG Bioscience, we continue to advance probiotic research through strain development and scientific validation. Our commitment to evidence-based innovation supports the development of differentiated probiotic ingredients for the global health and wellness industry.
Reference: Kwon et al. (2024). Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial. Scientific Reports, 14, 22384.
